NASDAQ:MIRM • US6047491013
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for MIRUM PHARMACEUTICALS INC (MIRM).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-23 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2026-03-04 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2026-02-26 | Citizens | Maintains | Market Outperform -> Market Outperform |
| 2026-02-26 | Leerink Partners | Maintains | Outperform -> Outperform |
| 2026-02-26 | TD Cowen | Maintains | Buy -> Buy |
| 2026-02-26 | RBC Capital | Maintains | Outperform -> Outperform |
| 2026-02-26 | Stifel | Maintains | Buy -> Buy |
| 2026-02-18 | RBC Capital | Initiate | Outperform |
| 2026-01-30 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2026-01-26 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2026-01-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-12-19 | Citizens | Maintains | Market Outperform -> Market Outperform |
| 2025-12-16 | Stifel | Maintains | Buy -> Buy |
| 2025-12-09 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2025-12-09 | Baird | Maintains | Outperform -> Outperform |
| 2025-12-09 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-11-05 | Citizens | Maintains | Market Outperform -> Market Outperform |
| 2025-11-05 | Cantor Fitzgerald | Maintains | Overweight -> Overweight |
| 2025-11-05 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-10-16 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-09-24 | TD Cowen | Initiate | Buy |
| 2025-09-12 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-08-11 | Stifel | Reiterate | Buy |
| 2025-08-08 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2025-08-07 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 186.374M 141.86% | 336.888M 80.76% | 521.312M 54.74% | 658.01M 26.22% | 801.28M 21.77% | 1.003B 25.17% | 1.301B 29.71% | 1.615B 24.14% | 1.914B 18.51% | 2.177B 13.74% | 2.216B 1.79% | |
| EBITDA YoY % growth | -98.325M 23.17% | -63.977M 34.93% | 2.108M 103.29% | -97.806M -4,739.74% | -95.208M 2.66% | -4.089M 95.70% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -109.154M 16.82% | -87.606M 19.74% | -22.136M 74.73% | -85.572M -286.57% | -1.956M 97.71% | 135.54M 7,029.08% | 430.01M 217.26% | 669.54M 55.70% | 907.98M 35.61% | 1.119B 23.24% | 1.145B 2.32% | |
| Operating Margin | -58.57% | -26.00% | -4.25% | -13.00% | -0.24% | 13.51% | 33.05% | 41.46% | 47.44% | 51.40% | 51.67% | |
| EPS YoY % growth | -3.97 1.17% | -1.85 53.40% | -0.47 74.59% | -0.97 -105.78% | 0.16 116.15% | 1.21 675.48% | 4.98 311.51% | 8.21 64.80% | 11.03 34.31% | 13.05 18.27% | 14.38 10.21% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -0.14 52.31% | -0.18 -46.29% | -0.04 -182.62% | 0.00 98.47% |
| Revenue Q2Q % growth | 150.87M 35.21% | 158.95M 24.39% | 162.33M 22.04% | 167.96M 12.78% |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -10.966M 27.77% | -11.616M -132.83% | -1.3M -149.94% | 2.472M 154.13% |
All data in USD
17 analysts have analysed MIRM and the average price target is 116.99 USD. This implies a price increase of 31.73% is expected in the next year compared to the current price of 88.815.
MIRUM PHARMACEUTICALS INC (MIRM) will report earnings on 2026-05-05, after the market close.
The consensus EPS estimate for the next earnings of MIRUM PHARMACEUTICALS INC (MIRM) is -0.14 USD and the consensus revenue estimate is 150.87M USD.
The expected long term growth rate for MIRUM PHARMACEUTICALS INC (MIRM) is 24.06%.